PH12022550056A1 - Dll3-targeting antibodies and uses thereof - Google Patents

Dll3-targeting antibodies and uses thereof

Info

Publication number
PH12022550056A1
PH12022550056A1 PH1/2022/550056A PH12022550056A PH12022550056A1 PH 12022550056 A1 PH12022550056 A1 PH 12022550056A1 PH 12022550056 A PH12022550056 A PH 12022550056A PH 12022550056 A1 PH12022550056 A1 PH 12022550056A1
Authority
PH
Philippines
Prior art keywords
dll3
antibodies
targeting antibodies
immunoglobulin
delta
Prior art date
Application number
PH1/2022/550056A
Other languages
English (en)
Inventor
David Andrew
Xinlei Chen
Abdul Khan
Jason Lewis
Ivo Lorenz
John T Poirier
Charles Rudin
Original Assignee
Memorial Sloan Kettering Cancer Center
Tri Inst Therapeutics Discovery Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Tri Inst Therapeutics Discovery Inst filed Critical Memorial Sloan Kettering Cancer Center
Publication of PH12022550056A1 publication Critical patent/PH12022550056A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2022/550056A 2019-07-11 2020-07-08 Dll3-targeting antibodies and uses thereof PH12022550056A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962872915P 2019-07-11 2019-07-11
PCT/US2020/041282 WO2021007371A1 (en) 2019-07-11 2020-07-08 Dll3-targeting antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PH12022550056A1 true PH12022550056A1 (en) 2023-04-12

Family

ID=74115317

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550056A PH12022550056A1 (en) 2019-07-11 2020-07-08 Dll3-targeting antibodies and uses thereof

Country Status (13)

Country Link
US (1) US12441789B2 (enExample)
EP (1) EP3997127A4 (enExample)
JP (2) JP7661299B2 (enExample)
KR (1) KR20220034167A (enExample)
CN (3) CN119080930A (enExample)
AU (1) AU2020310894A1 (enExample)
BR (1) BR112022000216A2 (enExample)
CA (1) CA3146566A1 (enExample)
CO (1) CO2022001195A2 (enExample)
IL (1) IL289585A (enExample)
MX (1) MX2022000325A (enExample)
PH (1) PH12022550056A1 (enExample)
WO (1) WO2021007371A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2718257T3 (enExample) * 2014-05-30 2018-04-14
BR112022000216A2 (pt) * 2019-07-11 2022-05-17 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a dll3 e usos dos mesmos
WO2022153195A1 (en) * 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
WO2022153194A1 (en) * 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
WO2022237647A1 (zh) * 2021-05-08 2022-11-17 上海齐鲁制药研究中心有限公司 针对dll3的结合分子及其应用
WO2023034557A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof
WO2023034555A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting dll3 and uses thereof
EP4396224A4 (en) * 2021-09-02 2025-11-12 Memorial Sloan Kettering Cancer Center Anti-DLL3 Antibodies and Their Uses
EP4454662A4 (en) * 2021-12-23 2025-04-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTI-DLL3 ANTIBODY AND PHARMACEUTICAL USE THEREOF, AND ANTIBODY-DRUG CONJUGATE CONTAINING AN ANTI-DLL3 ANTIBODY
KR20240149438A (ko) 2022-02-27 2024-10-14 베링거 인겔하임 인터내셔날 게엠베하 Cd277 및 종양-항원에 대한 이중특이적 항체
CN116003628A (zh) * 2022-08-15 2023-04-25 南京博安生物技术有限公司 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
WO2025184421A1 (en) * 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288253B2 (en) 2003-08-08 2007-10-30 Amgen Fremont, Inc. Antibodies directed to parathyroid hormone (PTH) and uses thereof
AU2007325872B2 (en) * 2006-11-08 2012-12-13 Macrogenics West, Inc. TES7 and antibodies that bind thereto
EP3907242A1 (en) 2010-01-29 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
WO2012013813A1 (en) 2010-07-30 2012-02-02 Gianluca Moroncini Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof
AU2013215254B2 (en) * 2012-01-31 2017-08-31 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
RU2014138474A (ru) * 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
WO2015127407A1 (en) * 2014-02-21 2015-08-27 Stemcentrx, Inc. Anti-dll3 antibodies and drug conjugates for use in melanoma
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
EP3221356B1 (en) 2014-11-20 2020-09-02 F.Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules against folr1 and cd3
BR112022000216A2 (pt) * 2019-07-11 2022-05-17 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a dll3 e usos dos mesmos

Also Published As

Publication number Publication date
AU2020310894A1 (en) 2022-02-03
EP3997127A1 (en) 2022-05-18
JP2022540611A (ja) 2022-09-16
KR20220034167A (ko) 2022-03-17
JP7661299B2 (ja) 2025-04-14
WO2021007371A1 (en) 2021-01-14
BR112022000216A2 (pt) 2022-05-17
CO2022001195A2 (es) 2022-03-08
CN114341182B (zh) 2024-09-10
JP2025156278A (ja) 2025-10-14
US20220348648A1 (en) 2022-11-03
CA3146566A1 (en) 2021-01-14
EP3997127A4 (en) 2023-08-23
CN119080930A (zh) 2024-12-06
IL289585A (en) 2022-03-01
CN118955717A (zh) 2024-11-15
US12441789B2 (en) 2025-10-14
MX2022000325A (es) 2022-03-25
CN114341182A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
WO2020172621A8 (en) Cd33 antibodies and methods of using the same to treat cancer
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
WO2022032003A3 (en) Anti-claudin 18.2 antibodies and uses thereof
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
NZ782442A (en) Antibodies that bind cd39 and uses thereof
EP4389226A3 (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
MX2022000325A (es) Anticuerpos dirigidos contra dll3 y usos de los mismos.
NZ734803A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
ZA202201464B (en) Anti-tigit antibodies and application thereof
MX2010001237A (es) Nuevos anticuerpos.
MX2023009715A (es) Anticuerpo de dominio individual biespecífico contra el ligando de muerte programada (pd-l1) y el cúmulo de diferenciación 47 (cd47) y uso del mismo.
PH12021553197A1 (en) Anti-cd47 antibodies and uses thereof
WO2022108976A3 (en) Anti-gpa33 multi-specific antibodies and uses thereof
MX2025003153A (es) Anticuerpos anti-ccr8
MX2022005718A (es) Anticuerpos tmem219 y usos terapeuticos de los mismos.
MX2025006929A (es) Anticuerpos contra la proteína 1 que contiene dominio de cub (cdcp1) y usos de estos
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.
WO2024031009A3 (en) Anti-cd24 antibodies and uses thereof
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
WO2022081443A3 (en) Anti-psma antibodies and uses thereof